Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979071 | 1.00 | HCAR2 (0.38) | HCAR2HCAR3OPRM1SLC6A9RIPK1 | |
| SCHEMBL981294 | 0.99 | HCAR2 (0.39) | HCAR2HCAR3OPRM1SLC6A9RIPK1 | |
| SCHEMBL979177 | 0.84 | GRIN2B (0.35) | HCAR2HCAR3HDAC1HDAC2 | |
| SCHEMBL12948254 | 0.83 | GRIN2B (0.36) | HCAR2HCAR3OPRM1HDAC1HDAC2 | |
| SCHEMBL12028357 | 0.81 | CALCRL (0.36) | HCAR2HCAR3OPRM1SLC6A9CALCRL | |
| SCHEMBL5654621 | 0.77 | HDAC4 (0.41) | HCAR2HCAR3OPRM1SLC6A9HDAC3 | |
| SCHEMBL979178 | 0.72 | HCAR3 (0.35) | HCAR2HCAR3OPRM1SLC6A9 | |
| SCHEMBL978532 | 0.71 | KMT2A (0.30) | — | |
| SCHEMBL12028354 | 0.71 | S1PR1 (0.31) | HCAR2HCAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL1273276 | 0.71 | HDAC4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507477-B2 | 3- and 6-quinolines with N-attached heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110306604-A1 | 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306604-A1 | 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | CALCRL, CCKBR, CCKAR | HCAR2 83/4885HCAR3 24/4885OPRM1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.